Fujifilm throws another billion at North Carolina cell culture facility

12 April 2024
fujifilm_large

Japanese conglomerate Fujifilm Holdings Corporation (TYO: 4901) is to invest a further $1.2 billion to expand its large-scale cell culture CDMO business in North Carolina, USA.

This brings the total investment in the Holly Springs facility to more than $3.2 billion, and adds significant large-scale production capacity to Fujifilm Diosynth Biotechnologies’ global network through its US and Europe manufacturing hubs.

The investment will generate an additional 680 jobs by 2031, also bringing the total number of new, highly skilled local jobs to 1,400 in Holly Springs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology